A phase IIA clinical study of anlotinib combined with Toripalimab (teriprizumab) injection and neoadjuvant radiotherapy and chemotherapy for resectable esophageal squamous cell carcinoma
Latest Information Update: 03 Aug 2020
At a glance
- Drugs Catequentinib (Primary) ; Toripalimab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Aug 2020 New trial record